Page last updated: 2024-11-12

zaragozic acid b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zaragozic acid B: structure given in first source; a fungal metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9940176
CHEMBL ID504845
SCHEMBL ID6130350
MeSH IDM0211815

Synonyms (17)

Synonym
zaragozic acid b
CHEMBL504845 ,
bdbm50292415
146389-61-9
unii-2af560r2hc
2af560r2hc ,
l-glycero-d-altro-pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13,14,15-heptadeoxy-10,12-dimethyl-15-phenyl-, 5-(6,12-tetradecadienoate), (5(6e,12e),7s,10xi,11xi,12xi)-
(1r,2s,3s,5s,6r,7r)-2,6-dihydroxy-5-[(e)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-7-[(6e,12e)-tetradeca-6,12-dienoyl]oxy-4,8-dioxabicyclo[3.2.1]octane-1,2,3-tricarboxylic acid
gtpl6061
SCHEMBL6130350
zaragozic acid b [mi]
l-glycero-d-altro-pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13,14,15-heptadeoxy-10,12-dimethyl-15-phenyl-, 5-((6e,12e)-6,12-tetradecadienoate)
Q27089280
(1s,3s,4s,5r,6r,7r)-4,7-dihydroxy-1-[(e)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-6-[(6e,12e)-tetradeca-6,12-dienoyl]oxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
(1s,3s,4s,5r,6r,7r)-4,7-dihydroxy-1-((e)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-en-1-yl)-6-(((6e,12e)-tetradeca-6,12-dienoyl)oxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
HY-130331
CS-0107332

Research Excerpts

Overview

Zaragozic acid B is a weak inhibitor of FPPase/GGPPase activities as compared to squalene synthase.

ExcerptReferenceRelevance
"Zaragozic acid B is a weak inhibitor of FPPase/GGPPase activities as compared to squalene synthase."( Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes.
Bansal, VS; Vaidya, S, 1994
)
1.01

Treatment

ExcerptReferenceRelevance
"Treatment with zaragozic acid B leads to an eightfold increase in the amount of farnesol produced by C."( Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid B.
Hornby, JM; Kebaara, BW; Nickerson, KW, 2003
)
0.88
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.00020.00020.552110.0000AID336318
Squalene synthaseRattus norvegicus (Norway rat)IC50 (µMol)0.00020.00020.45434.2000AID336318
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID336093Inhibition of bovine Ras FPTase1993Journal of natural products, Nov, Volume: 56, Issue:11
Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
AID336318Inhibition of rat liver squalene synthase by liqiud scintillation counting1993Journal of natural products, Nov, Volume: 56, Issue:11
Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
AID1346813Rat squalene synthase (Lanosterol biosynthesis pathway)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-01, Volume: 90, Issue:1
Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (71.43)18.2507
2000's2 (28.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]